OLYSIO
PeakNDAORALCAPSULEPriority Review
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OLYSIO is an oral small-molecule capsule approved by the FDA in November 2013 for use in hepatitis C virus (HCV) infection. The drug represents a protease inhibitor class therapeutic, though specific mechanism of action and indications are not detailed in available data. It is administered orally as part of combination antiviral regimens for chronic HCV.
Peak3.3 years to LOE
The product is in peak commercial lifecycle with high competitive pressure (8/10), suggesting a mature, densely competitive market with stable-to-declining team headcount in commercial roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on OLYSIO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.